Phase I/II study to assess the clinical pharmacology and safety of single ascending and multiple subcutaneous doses of PF-06881894 in women with non-distantly metastatic breast cancer

PURPOSE: To evaluate the pharmacodynamics (PD), pharmacokinetics (PK), and safety of single and multiple doses of PF-06881894 (pegfilgrastim-apgf; Nyvepria(™)), a biosimilar to reference pegfilgrastim (Neulasta(®)), in women with non-distantly metastatic breast cancer. METHODS: In Phase I (Cycle 0)...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Hsuan-Ming, Jones, Sarah Ruta, Morales, Serafin, Moosavi, Shahrzad, Zhang, Jeffrey, Freyman, Amy, Ottery, Faith D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8536579/
https://www.ncbi.nlm.nih.gov/pubmed/34618197
http://dx.doi.org/10.1007/s00280-021-04355-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8536579/
https://www.ncbi.nlm.nih.gov/pubmed/34618197
http://dx.doi.org/10.1007/s00280-021-04355-6

Ejemplares similares